The SPS CE Lunchtime Mini Course, chaired by Mark Deurinck, Novartis, is one of the highlights of the SPS Annual Meeting. In this course, three case studies will be presented by renowned safety pharmacology experts. Each case study will consist of a 15-minute presentation followed by a 5-min Q&A. The case studies will consist of the cardiovascular, central nervous or respiratory systems and will address studies conducted, issues/risks and risk mitigation in discovery, preclinical and/or clinical development of large and small molecules.
The informal atmosphere of this CE course promotes close and interactive interactions between the experts and the attendees allowing for deeper insights in how safety pharmacology liabilities are tackled in the process of drug development at different companies. (Lunch and beverages will be provided to course attendees.)
Following the session, the comment function within this blog tool (below within the blue bar) pemits you with an opportunity to further the discussion around this topic. SPS members can simply login at the top right if you do not see the comment option. Nonmembers can use the share option to further discusion on their own social network platforms.